Patient selection for balloon pulmonary angioplasty: Six-year results from a high volume PTE surgical center.
BPA
CTEPH
balloon pulmonary angioplasty
chronic thromboembolic pulmonary hypertension
pulmonary thromboendarterectomy
Journal
Pulmonary circulation
ISSN: 2045-8932
Titre abrégé: Pulm Circ
Pays: United States
ID NLM: 101557243
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
16
06
2022
revised:
17
08
2022
accepted:
12
09
2022
entrez:
3
11
2022
pubmed:
4
11
2022
medline:
4
11
2022
Statut:
epublish
Résumé
Chronic thromboembolic pulmonary hypertension (CTEPH) is the result of incompletely resolved pulmonary emboli (PE) that lead to chronic right heart failure. The two mechanical treatment options are pulmonary thromboendarterectomy (PTE) and balloon pulmonary angioplasty (BPA). There are no formal criteria for BPA patient selection and treatment decisions vary according to a center's experience with BPA and PTE. We performed a retrospective review of consecutive patients treated with PTE and BPA at UCSD from March 2015 to 2021. Clinical and hemodynamic data were collected. Patients were categorized according to the rationale for BPA. One hundred fifty three patients underwent 643 BPA sessions, and 1104 patients underwent PTE. Patients selected for PTE had worse baseline hemodynamics with mean pulmonary artery pressure 41.1 ± 11.7 versus 34.6 ± 11.2 mmHg,
Identifiants
pubmed: 36325508
doi: 10.1002/pul2.12148
pii: PUL212148
pmc: PMC9618287
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12148Informations de copyright
© 2022 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.
Déclaration de conflit d'intérêts
David S. Poch—Principal Investigator Janssen, Merck; Demosthenes Papamatheakis—Speaker: Janssen; Timothy Fernandes—Consulting: Bayer; Kim Kerr—Research Support: Bayer; Michael Madani—Consultant: Bayer, Johnson and Johnson, and Wexler Surgical; Nick H. Kim—Consultant: Bayer, Janssen, Merck, United Therapeutics, CTEPH.com Speaker: Bayer, Janssen. Other authors: None.
Références
Lancet Respir Med. 2022 Oct;10(10):961-971
pubmed: 35926542
Lancet Respir Med. 2017 Oct;5(10):785-794
pubmed: 28919201
Circulation. 2011 Nov 1;124(18):1973-81
pubmed: 21969018
Pulm Circ. 2021 May 24;11(2):20458940211007372
pubmed: 34104418
J Am Coll Cardiol. 2018 May 29;71(21):2468-2486
pubmed: 29793636
Eur Respir J. 2017 Jun 8;49(6):
pubmed: 28596435
Circ Cardiovasc Qual Outcomes. 2017 Nov;10(11):
pubmed: 29101270
N Engl J Med. 2013 Jul 25;369(4):319-29
pubmed: 23883377
Int J Cardiol. 2019 Aug 15;289:116-118
pubmed: 31060757
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Pulm Circ. 2021 May 24;11(2):20458940211007375
pubmed: 34104420
Eur Respir J. 2019 May 18;53(5):
pubmed: 31023842
Open Heart. 2020 Feb 27;7(1):e001144
pubmed: 32180986
Lancet Respir Med. 2022 Oct;10(10):949-960
pubmed: 35926544
Int J Cardiol. 2017 Jan 1;226:118-120
pubmed: 27810474
Int J Cardiol. 2019 Mar 1;278:232-237
pubmed: 30409735
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545969
Circulation. 2009 Sep 29;120(13):1248-54
pubmed: 19752321
Neth Heart J. 2020 Feb;28(2):81-88
pubmed: 31782109
J Thorac Cardiovasc Surg. 2014 Sep;148(3):1005-11; 1012.e1-2; discussion 1011-2
pubmed: 25129589
Interv Cardiol Clin. 2018 Jan;7(1):103-117
pubmed: 29157517
Eur Respir J. 2015 May;45(5):1293-302
pubmed: 25395036
Int J Cardiol. 2015 Mar 15;183:138-42
pubmed: 25662076
Eur Respir Rev. 2017 Mar 29;26(143):
pubmed: 28356405
Int J Cardiol. 2018 Dec 1;272S:69-78
pubmed: 30195840
Jpn J Radiol. 2016 Jun;34(6):423-31
pubmed: 27012964
J Thorac Cardiovasc Surg. 2022 Sep;164(3):696-707.e4
pubmed: 35361492